Boston Scientific Corporation (BSX)
Automate Your Wheel Strategy on BSX
With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BSX
- Rev/Share 13.5395
- Book/Share 16.505
- PB 4.5503
- Debt/Equity 0.5124
- CurrentRatio 1.6168
- ROIC 0.0878
- MktCap 110292183121.0
- FreeCF/Share 2.4449
- PFCF 30.4254
- PE 38.1552
- Debt/Assets 0.2843
- DivYield 0
- ROE 0.1253
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BSX | Erste Group | Buy | Hold | -- | -- | Oct. 3, 2025 |
| Upgrade | BSX | Oppenheimer | Perform | Outperform | -- | $125 | Sept. 8, 2025 |
| Initiation | BSX | Leerink Partners | -- | Outperform | -- | $118 | June 16, 2025 |
| Upgrade | BSX | Needham | Hold | Buy | -- | $113 | April 16, 2025 |
| Upgrade | BSX | Deutsche Bank | Hold | Buy | -- | $108 | Jan. 10, 2025 |
| Downgrade | BSX | Needham | Buy | Hold | -- | -- | Oct. 18, 2024 |
News
Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud
Published: February 23, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE:BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.
Read More
Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026.
Read More
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
Read More
Back on the Radar: Prior Picks Offer Fresh Opportunity
Published: February 18, 2026 by: Barrons
Sentiment: Positive
Sometimes the best new ideas are simply old winners ready for another run.
Read More
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific BSX reported its fourth-quarter 2025 results on Feb. 4. Both top and bottom lines exceeded the company's guidance ranges and topped the respective Zacks Consensus Estimate.
Read More
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Published: February 09, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER Y.
Read More
Reassessing The Boston Scientific Bull Thesis
Published: February 06, 2026 by: Forbes
Sentiment: Negative
On Wednesday, Boston Scientific (BSX) experienced a loss of nearly one-fifth of its market capitalization in a single trading session. The stock finished at $75.50, reaching a 52-week low, with a volume approximately six times greater than the 3-month average.
Read More
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: February 06, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 4, 2026, Boston Scientific.
Read More
What Happened To Boston Scientific Stock?
Published: February 05, 2026 by: Forbes
Sentiment: Negative
Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was marked by a drastic, high-volume liquidation event that quickly erased months of gains.
Read More
Investors in Boston Scientific Corporation (BSX) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
Published: February 05, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 5, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.
Read More
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Read More
BSX Stock Dips in Premarket Trading Despite Q4 Earnings, Revenue Beat
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.
Read More
Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Boston Scientific Profit, Sales Rise but Issues Soft Guidance
Published: February 04, 2026 by: WSJ
Sentiment: Neutral
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Read More
Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Read More
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Neutral
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (Raytheon), Capital One and Somnigroup. In addition to Insmed and BAE, we also added to L3Harris, a global aerospace and defense company.
Read More
Calls of the Day: Wynn, Cummins, Boston Scientific, Applovin and Monster Beverage
Published: January 26, 2026 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
PAHC vs. BSX: Which Stock Is the Better Value Option?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Read More
Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
How Low Can Boston Scientific Stock Go When Markets Turn Sour?
Published: January 16, 2026 by: Forbes
Sentiment: Negative
Boston Scientific (BSX) shares have decreased by 8.5% over the past 5 trading days. This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra acquisition, yet such significant declines often raise a challenging question: is this weakness transitory, or does it indicate more profound issues within the company?
Read More
Boston Scientific Corporation (BSX) M&A Call Transcript
Published: January 15, 2026 by: Seeking Alpha
Sentiment: Neutral
Boston Scientific Corporation (BSX) M&A Call Transcript
Read More
Boston Scientific to acquire Penumbra in $14.5B deal
Published: January 15, 2026 by: Proactive Investors
Sentiment: Positive
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.
Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), Clearwater Analytics Holdings, Inc. (NYSE - CWAN)
Published: January 15, 2026 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Read More
BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific stock may rebound after agreeing to buy Valencia Technologies, adding the FDA-approved eCoin ITNS device to expand its Urology portfolio.
Read More
Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach
Published: January 15, 2026 by: Invezz
Sentiment: Positive
Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions in the global medical technology sector this year.
Read More
About Boston Scientific Corporation (BSX)
- IPO Date 1992-05-19
- Website https://www.bostonscientific.com
- Industry Medical - Devices
- CEO Michael F. Mahoney
- Employees 53000